Literature DB >> 24115818

Inflammatory bowel disease serology in Asia and the West.

Lani Prideaux1, Michael A Kamm, Peter De Cruz, Daniel R van Langenberg, Siew C Ng, Iris Dotan.   

Abstract

AIM: To study serological antibodies in Caucasians and Asians, in health and inflammatory bowel disease (IBD), in Australia and Hong Kong (HK).
METHODS: Anti-glycan antibodies [anti-chitobioside (ACCA), anti-laminaribioside (ALCA)], and anti-mannobioside (AMCA), anti-Saccharomyces cervisiae (gASCA); and atypical perinuclear anti-neutrophil cytoplasmic antibody (pANCA) were tested in IBD patients, their unaffected relatives, and healthy controls in Australia and HK (China). Antibody status (positive or negative) and titre was compared between subjects of different geography, ethnicity and disease state.
RESULTS: Ninety subjects were evaluated: 21 Crohn's disease (CD), 32 ulcerative colitis (UC), 29 healthy controls, and 8 IBD patient relatives. Forty eight subjects were Australian (29 Caucasian and 19 ethnic Han Chinese) and 42 were from HK (all Han Chinese). Caucasian CD patients had a significantly higher antibody prevalence of gASCA (67% vs 3%, P < 0.001), ALCA (44% vs 6%, P = 0.005), and AMCA (67% vs 15%, P = 0.002), whereas HK CD patients had a higher prevalence of only AMCA (58% vs 25%, P = 0.035), when compared with UC and healthy subjects in both countries. Caucasian CD had significantly higher gASCA prevalence (67% vs 0%, P < 0.001) and titre (median 59 vs 9, P = 0.002) than HK CD patients. Prevalence and titres of ALCA, ACCA and AMCA did not differ between CD in the two countries. Presence of at least one antibody was higher in Caucasian than HK CD patients (100% vs 58%, P = 0.045). pANCA did not differ between countries or ethnicity.
CONCLUSION: Serologic CD responses differ between HK Asian and Australian Caucasian patients. Different genetic, environmental or disease pathogenic factors may account for these differences.

Entities:  

Keywords:  Anti-Saccharomyces cervisiae antibodies; Anti-chitobioside antibodies; Anti-laminaribioside antibodies; Anti-mannobioside antibodies; Asia; Atypical perinuclear anti-neutrophil cytoplasmic antibodies; Crohn’s disease; Ethnic; Serological antibodies; Ulcerative colitis

Mesh:

Substances:

Year:  2013        PMID: 24115818      PMCID: PMC3787351          DOI: 10.3748/wjg.v19.i37.6207

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  45 in total

1.  CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients.

Authors:  B Vander Cruyssen; H Peeters; I E A Hoffman; D Laukens; P Coucke; D Marichal; C Cuvelier; E Remaut; E M Veys; H Mielants; M De Vos; F De Keyser
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

2.  Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease.

Authors:  E Israeli; I Grotto; B Gilburd; R D Balicer; E Goldin; A Wiik; Y Shoenfeld
Journal:  Gut       Date:  2005-09       Impact factor: 23.059

Review 3.  Anti-glycan antibodies as biomarkers for diagnosis and prognosis.

Authors:  N Dotan; R T Altstock; M Schwarz; A Dukler
Journal:  Lupus       Date:  2006       Impact factor: 2.911

4.  NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives.

Authors:  Shane M Devlin; Huiying Yang; Andrew Ippoliti; Kent D Taylor; Carol J Landers; Xiaowen Su; Maria T Abreu; Konstantinos A Papadakis; Eric A Vasiliauskas; Gil Y Melmed; Phillip R Fleshner; Ling Mei; Jerome I Rotter; Stephan R Targan
Journal:  Gastroenterology       Date:  2006-11-10       Impact factor: 22.682

5.  The prevalence and clinical significance of perinuclear anti-neutrophil cytoplasmic antibody in Korean patients with ulcerative colitis.

Authors:  Jin Ha Lee; Jae Hee Cheon; Eun Soo Kim; Moon Jae Chung; Wonseok Kang; Duk Hwan Kim; You Jung Ha; Jae Jun Park; Tae Il Kim; Won Ho Kim
Journal:  Dig Dis Sci       Date:  2009-06-09       Impact factor: 3.199

6.  Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease.

Authors:  Iris Dotan; Sigal Fishman; Yaara Dgani; Mikael Schwartz; Amir Karban; Aaron Lerner; Oori Weishauss; Larissa Spector; Avi Shtevi; Rom T Altstock; Nir Dotan; Zamir Halpern
Journal:  Gastroenterology       Date:  2006-08       Impact factor: 22.682

Review 7.  Etiopathogenesis of inflammatory bowel diseases.

Authors:  Silvio Danese; Claudio Fiocchi
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

8.  Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn's disease behavior.

Authors:  Florian Rieder; Stephan Schleder; Alexandra Wolf; Andrea Dirmeier; Ulrike Strauch; Florian Obermeier; Rocio Lopez; Larissa Spector; Ella Fire; Jennifer Yarden; Gerhard Rogler; Nir Dotan; Frank Klebl
Journal:  Inflamm Bowel Dis       Date:  2010-02       Impact factor: 5.325

9.  Clinical significance of anti-Saccharomyces cerevisiae antibody (ASCA) in Korean patients with Crohn's disease and its relationship to the disease clinical course.

Authors:  B C Kim; S Park; J Han; J H Kim; T I Kim; W H Kim
Journal:  Dig Liver Dis       Date:  2007-05-24       Impact factor: 4.088

10.  Ethnic and socio-cultural specificities in Tunisia have no impact on the prevalence of anti-Saccharomyces cerevisiae antibodies in Crohn's disease patients, their relatives or associated clinical factors.

Authors:  Ines Hadrich; Peggy Vandewalle; Fatma Cheikhrouhou; Fattouma Makni; Mohamed Salah Krichen; Boualem Sendid; Annie Standaert-Vitse; Ali Ayadi; Daniel Poulain
Journal:  Scand J Gastroenterol       Date:  2007-06       Impact factor: 2.423

View more
  7 in total

Review 1.  Host-microbiome interaction in Crohn's disease: A familiar or familial issue?

Authors:  Andrea Michielan; Renata D'Incà
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

2.  Antibodies against glycoprotein 2 display diagnostic advantages over ASCA in distinguishing CD from intestinal tuberculosis and intestinal Behçet's disease.

Authors:  Shulan Zhang; Jing Luo; Ziyan Wu; Dirk Roggenbuck; Peter Schierack; Dirk Reinhold; Ji Li; Xiaofeng Zeng; Fengchun Zhang; Jiaming Qian; Yongzhe Li
Journal:  Clin Transl Gastroenterol       Date:  2018-02-15       Impact factor: 4.488

3.  Cutaneous Vasculitis, Interstitial Pneumonia with Crazy-Paving Appearance, and Positive pANCA in a Patient with Severe Crohn's Disease.

Authors:  Guang-Liang Chen; Juan Wang; Bao-Zhen Li; Li-Mei Li; Han-You Mo; Shuang Ye
Journal:  Case Rep Gastrointest Med       Date:  2014-08-14

4.  Colectomy Rates for Ulcerative Colitis Differ between Ethnic Groups: Results from a 15-Year Nationwide Cohort Study.

Authors:  Ravi Misra; Alan Askari; Omar Faiz; Naila Arebi
Journal:  Can J Gastroenterol Hepatol       Date:  2016-12-15

5.  A combination of circulating microRNA-375-3p and chemokines CCL11, CXCL12, and G-CSF differentiate Crohn's disease and intestinal tuberculosis.

Authors:  Susree Roy; Suchandrima Ghosh; Mallica Banerjee; Sayantan Laha; Dipanjan Bhattacharjee; Rajib Sarkar; Sujay Ray; Arko Banerjee; Ranajoy Ghosh; Aniket Halder; Alakendu Ghosh; Raghunath Chatterjee; Simanti Datta; Gopal Krishna Dhali; Soma Banerjee
Journal:  Sci Rep       Date:  2021-12-02       Impact factor: 4.379

6.  Role of Serum Proteinase 3 Antineutrophil Cytoplasmic Antibodies in the Diagnosis, Evaluation of Disease Severity, and Clinical Course of Ulcerative Colitis.

Authors:  So Imakiire; Hidetoshi Takedatsu; Keiichi Mitsuyama; Hideto Sakisaka; Kozo Tsuruta; Masaru Morita; Nobuaki Kuno; Koichi Abe; Sadahiro Funakoshi; Hideki Ishibashi; Shinichiro Yoshioka; Takuji Torimura; Fumihito Hirai
Journal:  Gut Liver       Date:  2022-01-15       Impact factor: 4.519

7.  Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease.

Authors:  Shulan Zhang; Ziyan Wu; Jing Luo; Xuefeng Ding; Chaojun Hu; Ping Li; Chuiwen Deng; Fengchun Zhang; Jiaming Qian; Yongzhe Li
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.